References
- Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004;109:2203–2206
- Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999–3054
- Sanchez GC, Harizi H, Nurden A, Coste P, Jais C, Nurden P. A case of profound and prolonged tirofiban-induced thrombocytopenia and its correction by intravenous immunglobulin G. International society on thrombosis and haemostasis. J Thromb Haemost 2007;5:1068–1070
- Teke HU, Teke D. Profound thrombocytopenia related with tirofiban: Will it be enough to only stop medicine? Platelets 2013;24:335--337
- Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, Lind RN, Pereira J, Aster RH. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GpIIb/IIIa. Blood 2002;100:2071–2076
- Sakellariou D, Pastromas S, Koulouris S, Manolis A. First report of tirofiban-induced anemia. Tex Heart Inst J 2009;36:55–57